List of Briviact drug patents

Briviact is owned by Ucb Inc.

Briviact contains Brivaracetam.

Briviact has a total of 2 drug patents out of which 0 drug patents have expired.

Briviact was authorised for market use on 12 May, 2016.

Briviact is available in solution;intravenous dosage forms.

Briviact can be used as treatment of partial-onset seizures in patients 4 years of age and older.

The generics of Briviact are possible to be released after 09 April, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6911461 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Aug 27, 2024

Drugs and Companies using BRIVARACETAM ingredient

Market Authorisation Date: 12 May, 2016

Treatment: Treatment of partial-onset seizures in patients 4 years of age and older

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of BRIVIACT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in